Acadia Pharmaceuticals News and Activities

Acadia Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Acadia Pharmaceuticals is a company listed under the stock ticker ACAD (US).

View the org chart displaying its 43 main executives

Most searched biographies at Acadia Pharmaceuticals

• Catherine Owen, Chief Executive Officer and Director
• Laura Brege, Director
• Stephen Biggar, Chairman of the Board

Popular executive movements at Acadia Pharmaceuticals

• Jonathan Poole has joined the company as Director  (posted on March 5 2026).

Create your alert
to follow the executive moves at Acadia Pharmaceuticals.

Acadia Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Acadia Pharmaceuticals

• Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
• Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
• Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
• Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
• Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
• Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
• Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
• Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
• Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
• Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
• View more press releases Close

Social media about Acadia Pharmaceuticals

• Acadia Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Acadia Pharmaceuticals on LinkedIn, X (Twitter) & YouTube